Interim CEO and Director
Dr Tracie RamsdaleTracie is one of the founders of Alchemia Limited and led the company’s development as its General Manager and Chief Executive Officer from 1998 to 2007. Tracie joined the Alchemia Board in July 2003. During her tenure as CEO, Tracie led the development of fondaparinux and Alchemia's drug discovery technology.
Prior to establishing Alchemia, Tracie was a Principal Investigator and Commercial Manager of the Centre for Drug Design and Development at the University of Queensland. Tracie is an adjunct Professor at the School of Chemical and Molecular Biosciences, University of Queensland, a member of the Australian Federal Government Advisory Council on Intellectual Property, a Fellow of the Australian Academy of Technological Sciences and Engineering, and a member of the Australian Institute of Company Directors.
Tracie holds a PhD in Biochemistry from the University of Queensland, a Master of Pharmacy from the Victorian College of Pharmacy and a Bachelor of Applied Science (Chemistry) from the Royal Melbourne Institute of Technology. She currently provides independent consulting advice to the biotechnology industry, academia and government.
Chief Scientific Officer
Dr Tracey MynottTracey is one of the inventors of the Detach® technology, being involved with its development in the 1990s, and more recently with the development of the new formulation.
Tracey has a PhD in the pathogenesis of enteric infections with a particular focus on the Detach® concept and enterotoxigenic E. coli infections. She has conducted post-doctoral studies at The Center for Vaccine Development at the University of Maryland in USA, the Division of Gastroenterology within The Royal College of Physicians and Surgeons at Columbia University in New York, the Digestive Diseases Research Centre at the Medical College of St Bartholomew''s Hospital in London and in the Department of Biochemistry, Imperial College in London.
Tracey is the former Head of Business Development at the Queensland Institute of Medical Research, one of Australia''s most prestigious research organisationss. She has also held senior management positions in public and private Australian and UK biotechnology companies, where she has successfully discovered and patented several technologies, devised and directed drug development and clinical programs, developed and implemented business strategies, including licensing, acquisitions, capital raising and marketing.
Chief Operating Officer
Dr Michael WestMichael joined Anatara Lifesciences as Chief Operating Officer in 2016. He brings to the role a wealth of experience from over 25 years in the pharmaceutical industry internationally. In his career Michael has worked in US based large pharmaceutical companies, Australian Biotechnology companies and as a consultant to Regulatory Authorities as well as public and private pharma-industry companies in Asia-Pacific, the USA and Europe.
Originally trained as a medicinal chemist, Michael was a member of the team at SmithKline Beecham that led the discovery of HIV drugs in the early 1990’s. His interest in the chemistry of medicines inevitably led to roles in drug development and drug manufacturing. He has applied these skills to the successful development of a generic form of fondaparinux sodium, now marketed globally by Dr Reddy’s Laboratories. A product that is considered one of the most technically challenging drug molecules ever to have reached the market. Michael has also developed new dosage forms for anti-cancer drugs and most recently managed the Chemistry and Manufacture of Anatara’s products.
As Chief Operating Officer and a qualified Patent & Trademarks Attorney, Michael manages Anatara’s intellectual property portfolio, has primary oversight over Chemistry & Manufacturing, and provides operational leadership on business process within Anatara.
Chief Development Officer
Dr Tracey BrownTracey joined Anatara in September 2016 where she is responsible for the direction and management of the human product development program.
After obtaining her PhD in Biochemistry from Monash University, Tracey worked in academic and commercial research institutions in the USA, Europe and Australia where she focused on developing products for the treatment of cancer, inflammation and anti-aging.
Over the last 20 years, Tracey has built, managed and lead international product development teams which have taken products from conception through to registration. Through this process, Tracey has developed extensive experience in the identification and evaluation of suitable commercialisation assets, manufacture of chemical and biological therapeutics, development and implementation of preclinical and clinical development plans, clinical program management, regulatory affairs, interaction with international regulatory agencies and product reimbursement processes.
Prior to joining Anatara, Tracey was a co-founder of the ASX-listed company, Meditech; the Chief Scientific Officer of Alchemia and has acted as a director on the board of both listed and private biotechnology companies. Tracey also holds an adjunct Associate Professorship at Monash University where she participates in the commercialisation of research and the mentoring of academic researchers to assist in their transition into the biotechnology industry.
Hayley van der MeerHayley has extensive experience in the medical diagnostics and agricultural biotechnology industries, holding positions in both Australia and the USA with ASX listed diagnostics manufacturer, Panbio Limited, the former Molecular Plant Breeding Cooperative Research Centre (MPB CRC), and most recently with ASX listed Leaf Energy Ltd. Hayley specialises in sales and marketing, communications, public relations/investor relations, commercialisation of new technology, technology transfer, intellectual property management and project management.
Hayley holds a Bachelor of Biomedical Science from Griffith University and a Graduate Diploma in Marketing Management from Central Queensland University.